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Discarded human donor organs have been shown to provide decellularized extracellular matrix (dECM)
scaffolds suitable for organ engineering. The quest for appropriate cell sources to satisfy the need of
multiple cells types in order to fully repopulate human organ-derived dECM scaffolds has opened new
venues for the use of human pluripotent stem cells (hPSCs) for recellularization. In addition, three-
dimensional (3D) bioprinting techniques are advancing towards the fabrication of biomimetic cell-
laden biomaterial constructs. Here, we review recent progress in decellularization/recellularization and
3D bioprinting technologies, aiming to fabricate autologous tissue grafts and organs with an impact in
regenerative medicine.Introduction
Regenerative medicine holds the promise to replace or regenerate
human cells, tissue or organs in order to restore or establish the
normal function lost due to disease or damage [1]. By the combi-
nation of novel biomaterials with cells, one of the aims of regen-
erative medicine is to create autologous tissue grafts for future
replacement therapies [2,3]. In the last three years, discarded
human donor organs, such as kidney [4,5], lung [6], heart [7],
and liver [8], have been used to obtain decellularized extracellular
matrix (dECM) scaffolds, proving their potential application in
tissue engineering. Despite the translational value of these
advances, we are still far to generate relevant tissues for immediate
clinical applications.Please cite this article in press as: E. Garreta, et al., Mater. Today (2017), http://dx.doi.org/10
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j.mattod.2016.12.005 The use of organ-derived dECM scaffolds for bioengineering
of human-scale patient-specific organs using hPSCs is envi-
sioned as a major platform for therapeutic applications
(reviewed in [9]). Interestingly, the concept of organ printing
has lately taken center stage due to recent three-dimensional
(3D) bioprinting advancements (reviewed in [10–13]). Current
3D bioprinting techniques have shown to simultaneously de-
posit combinations of different cell types encapsulated within
biomimetic hydrogels via a layer-by-layer process, leading to the
generation of 3D bioinspired tissue constructs (reviewed in
[10,12,14,15]) [16–20]. Such approach could offer new
venues when translating hPSCs-related technologies to a
high-throughput 3D setup (e.g., patient induced pluripotent
stem cells (iPSCs)-derived organoid screening platforms)
(reviewed in [21])..1016/j.mattod.2016.12.005
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.1016/
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FIGURE 1
Timeline of key events leading to whole organ decellularization
methodologies and major milestones using hPSC-derived cells to
repopulate organ-derived dECM scaffolds (*).
BOX 1
Potential of dECM scaffolds to recapitulate tissues and organs
 Preservation of dECM ultrastructure and composition induce favorable
tissue organization and remodeling (reviewed in [23,24,36]).
 dECM can modulate cell behavior: attachment, migration and
differentiation (reviewed in [23,24,36]) [39,40,43,44].
 dECM do not elicit immune-mediated rejection, since ECM components
are largely and highly conserved across species [46,47].
 dECM exhibit suitable mechanical performance, similar to that of their
native counterparts (reviewed in [23,24,36]) [41].
 dECM promote constructive remodeling response, as shown for a variety
of tissues in both pre-clinical and clinical studies (reviewed in [42]) [45].
 The potential advantage of dECM organ specificity ensures the
maintenance of selected cell functions and phenotypes (reviewed in [38])
[39].
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build up tissue- and organ-like structures either by the use of
organ-derived dECM scaffolds (reviewed in [22–27]) or 3D bio-
printing techniques (reviewed in [10,12,14,15]) [16–20]. However,
the bioengineering of vascularized human-scale organ analogues
with optimal functional activity still requires much effort from
multidisciplinary research groups before this can become a reality.
Here, we review the latest advancements in the application of
decellularization/recellularization technology for the generation
of autologous tissue grafts taking advantage of hPSCs. We also
examine how 3D bioprinting technologies may benefit from
hPSCs derivatives to fabricate human organ analogues.
The advent of decellularization technology
Tissue-specific extracellular matrix (ECM) through
decellularization of tissues and organs
Pioneer findings on the production of tissue-specific ECM were
first reported in the 1970s and 1980s [28,29]. Despite these major
steps, it was not until 10 years later that Badylak and coworkers
generated intact acellular small intestinal submucosa matrices by
mechanically removing all mesenteric tissues while leaving the
trilaminate connective tissue layers intact [30]. Indeed, such ma-
trices demonstrated healing capacity in a dog model for Achille’s
tendon repair [30]. Soon, different works on decellularization of
other simple tissues such as skin [31], vascular tissue [32], heart
valves [33] and bladder [34] showed promising results on the
generation of biological scaffolds for biomedical applications,
representing a realistic alternative to the use of synthetic bioma-
terial scaffolds. From that moment, further works began to apply
decellularization methodologies for the fabrication of dECM slices
from complex organs such as liver [35].
In 2008, the seminal work by Ott and coworkers, who success-
fully generated whole rat acellular hearts by means of perfusion
decellularization, represented a breakthrough in the field of tissue
engineering and the beginning of the era of whole organ decel-
lularization technology [36]. Over the last years, different research
groups following similar approaches have reported the possibility
to derive full-scale dECM scaffolds from different organs including
liver, heart, lungs, and kidneys; and multiple species including
mouse, rat, pig, rhesus monkey, and human (reviewed in [22,23])
[37]. The main milestones on decellularization technology are
summarized in Fig. 1.
In vivo the composition and ultrastructure of ECM is in constant
remodeling by the resident cells depending on the metabolic and
mechanical demands of the tissue, a concept called ‘dynamic
reciprocity’ [38]. Such dynamic remodeling may be altered during
injury or disease, leading to modifications in the composition and
biophysical properties of the ECM, and ultimately, compromising
organ function. Accordingly, it has been suggested that ‘organ
specificity’, may determine why cells belonging to a specific organ
exhibit an innate preference towards dECM scaffolds derived from
the organ of origin [39,40]. Along this line, Nakayama and co-
workers showed that human embryonic stem cells (hESCs) differ-
entiated into renal-like cells when seeded onto rhesus monkey
kidney dECM, but this was not the case when lung dECM was used
instead [40]. The main hypothesis supporting such findings relies
on the idea that specific ECM proteins are distinctively distributed
along the different compartments of the organ as footprints fromPlease cite this article in press as: E. Garreta, et al., Mater. Today (2017), http://dx.doi.org/10
2resident cells. Interestingly, site-specific ECM micromechanical
properties have been described to delimitate different tissue
regions [41].
Overall, dECM scaffolds provide a complex site-specific combi-
nation of biochemical and mechanical cues, which have been
hypothesized to guide cell adhesion, proliferation and differentia-
tion during recellularization and further tissue formation
(reviewed in [42]) [39–41,43–45]. The main advantages using
dECM scaffolds for the de novo biofabrication of tissues and organs
are summarized in Box 1.
Methods of decellularization
Decellularization techniques aim to remove all the cells from a
tissue or organ while preserving the native ECM composition and
architecture integrity. As such, tissue and organ decellularization,
can lead to the production of 3D dECM scaffolds retaining their
biological activity and mechanical properties. If effective, dECM
scaffolds should not elicit immune-mediated rejection after im-.1016/j.mattod.2016.12.005
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action and peculiarities of each kind of decellularization agents
employed, as widely discussed elsewhere (reviewed in [48–50]). In
general, the optimal decellularization protocol will generate a
DNA-free dECM scaffold by finding the right compromise between
the duration and complexity of the treatment and the conserva-
tion of the desired compositional, structural and mechanical
properties of the generated dECM construct.
With respect to the techniques used to infuse the decellulariza-
tion agents within all regions of the organ, perfusion through the
vasculature and immersion/agitation are nowadays the most
employed, though others techniques have been also described
(e.g., pressure gradient [51,52], supercritical fluid [53]). Perfusion
decellularization takes advantage of the innate vasculature of the
organ to deliver the decellularization agents across the entire
organ. Such approach is often performed in organs in which its
main artery can be cannulated for perfusion with decellularization
solutions under physiologic perfusion pressures. In their seminal
work, Ott and coworkers developed a protocol for whole rat heart
decellularization using a homemade bioreactor to perfuse 1%
sodium dodecyl sulfate (SDS) through the coronary vasculature,
showing that 12 hours perfusion at a physiological pressure suf-
ficed to yield a fully decellularized rat heart [36]. The same research
group subsequently applied a similar approach to decellularize
whole rat lungs [54] and kidneys [55]. For lung decellularization,
both the airway and vascular compartments were investigated to
deliver the decellularization solutions, rendering in all cases acel-
lular organ scaffolds with preserved ECM composition, micro-
structure and 3D architecture [54,56–59]. Overall, perfusion
decellularization is the preferred technique to decellularize whole
organs, especially in large animals or humans [4–8,58,60–63].
On another hand, in immersion-based decellularization proto-
cols, the tissue or organ of interest is submerged into the decel-
lularization solutions while being subjected to agitation. In this
way, decellularization agents enter through the tissue by diffusion.Please cite this article in press as: E. Garreta, et al., Mater. Today (2017), http://dx.doi.org/10
BOX 2
Methods of decellularization
Perfusion 
Mode of action  Infusion of the decellularization agents through the 
vasculature
 Preferred when decellularizing large animal or hum
organs
Advantages  Facilitates homogeneous exposure to the decellulari
reagents and removal of cellular content
 The possibility to apply physiological perfusion pre
would favor preservation of tissue ECM composition 
architecture
 Controlled perfusion conditions by the use of biore
enhances the robustness and efficiency of the proces
Disadvantages  Unappropriate perfusion pressures can disrupt ECM
impact on the viscoelastic behavior of the dECM scaf
Optimization is required for each tissue/organ
 Needs cannulation of the main organ artery 
 This method usually needs the use of specific perfu
bioreactors
References [4–8,54,56–63] The duration of the protocol will then depend on the initial tissue
thickness and cell density. Such approach is mainly used on tissue
samples that do not have easy access to the vascular network (e.g.,
skeletal muscle, skin) [64–66], as well as on organ slices typically
obtained from a segmental resection. Box 2 summarizes the
advantages and disadvantages of the different methods of decel-
lularization discussed in this review.
Due to the large diversity of decellularization protocols and
tissue sources reported so far, there has been the necessity to
establish common criteria to evaluate the effectiveness of any
decellularization process. Decellularization requirements and as-
sociated methodologies are summarized in Box 3.
Although successful decellularization was achieved for many
organs, still much effort should be directed on the definition of
standardized decellularization protocols with the final goal to
advance in the creation of biocompatible and personalized organ
scaffolds for clinical applications. For that, issues including bio-
degradation, cytocompatibility, pathogenicity and immunogenic-
ity should also be further studied (reviewed in [67]).
Recellularization of whole organ dECM scaffolds
One of the major issues in the field of organ bioengineering is the
precise positioning of specific cell types inside their corresponding
specific organ compartment. Methods of cell seeding into whole
organ-derived dECM scaffolds will largely depend on the organ
itself and usually will require the use of bioreactors. Complex
organs including kidney, heart, lung, and liver entail the develop-
ment of challenging cell seeding and culture methods to promote
tissue formation and maturation. Oxygen diffusion across an
engineered tissue is limited to a maximum tissue thickness of
200 micrometers (reviewed in [68]), meaning that higher tissue
thicknesses must require functional vasculature to supply the cells
with oxygen and nutrients as well as facilitate the removal of
metabolic waste products. In this regard, bioreactor technology for
whole organ engineering still needs to overcome many issues:.1016/j.mattod.2016.12.005
Immersion/agitation
organ  Immersion of the tissue or organ into the decellularization
solutions while shaking
an  Used when the access to the vasculature is difficult or
absent
zation  Mechanical agitation facilitates cellular content removal
ssures
and
 Easy and fast procedure when decellularizing small animal
organs or tissues, and human tissues obtained from
segmental resections
actors
s
 Does not need overly specific bioreactor equipment
 and
fold.
 Decellularization conditions (e.g., agitation, reagents’
exposure time) have to be optimized depending on the
tissue thickness. Excessive agitation can disrupt ECM
 It is an unreliable method when decellularizing large
animal or human whole organs
sion  This method usually needs increasing times of exposure to
the decellularization agents when compared to perfusion
[39,64–66]
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BOX 3
Established criteria for effective decellularization
Requirement Methodology Outcome for effective decellularization References
Removal of cells
and DNA content
 Decellularized tissues should accomplish  Avoid adverse cell and host response as well
as negative tissue remodeling and
inflammation responses after implantation
[34] (reviewed in [48])
(i) <50 ng of double-stranded DNA (dsDNA)
per mg of dry weight dECM, as quantified by
commercially available dsDNA intercalators
such as PicoGreen and gel electrophoresis
(ii) <200 bp DNA fragment length, analyzed
by gel electrophoresis
 Histological stainings (Hematoxylin and
Eosin, Masson’s Trichome, Movat’s
Pentachrome, or Safrin O) or
immunohistochemistry analysis in dECM
should denote the lack of visible nuclei (as
stained DAPI or Hoechst). These can be used
to qualitatively detect if nuclei content,
cytoplasmic proteins or some extracellular
components are still present after
decellularization
Quantification of
residual detergents
 Quantification of remnant SDS can be
determined using Stains-All reagent
 Avoid toxic effects form these
decellularization agents, ensuring cell
viability during dECM scaffold
recellularization.
[67]
 Similarly residual Triton X-100 can be
quantified by using derivative
spectrophotometry.
 Undetectable amounts of such components
are desired
Preservation of
ECM components
 Qualitative evaluation by
immunohistochemistry analysis of the main
ECM proteins including collagens, laminin,
fibronectin and elastin
 Retention of the main basement membrane
components and structural ECM proteins as
compared to their native counterparts
[8,43,56,84]
 Quantitative colorimetric assays are
employed to determine the amount of
collagen, elastin and glycosaminoglycans
using commercially available Sircol, Fastin
and Blyscan kits, respectively
 Mass spectrometry-based proteomics
allows precise identification of matrisome
proteins and other tissue-specific proteins
Maintenance of
3D architecture
and vascular
integrity
 Micro- and nano-architecture of relevant
parenchymal structures of each organ can be
assessed by scanning electron microscopy
(SEM)
 Conservation of the main structural features
specific of each organ, which will facilitate
tissue organization and maintenance of
specific cell phenotypes
[4,5] (reviewed in [22,36])
 Conservation of the hierarchical vascular
bed of the organ after decellularization can
be evaluated by MicroCT, dye or microbeads
perfusion assays, angiography or corrosion
casting
 Conservation of the hierarchical vascular
bed of the organ, which is essential to further
achieve an effective recellularization
outcome
Biomechanical
performance
 Traditional material science and
engineering techniques including uni- or bi-
axial mechanical testing and atomic force
microscopy (AFM) have been mainly used for
mechanical testing on produced
decellularized scaffolds
 Optimal dECM scaffold mechanical
properties (mechanical strength and
viscoelastic behavior), that following
recellularization should be similar to those of
their native counterparts
[4,41,56,63]
 Lung mechanics has been assessed using
pressure-volume curves and measuring force
tension relationships in linear strips of
decellularized lungs
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BOX 4
Bioreactor requirements for recellulatization of whole organ dECM
scaffolds
 Include independent access lines for cell seeding through vascular and
non-vascular routes
 Integrate pressure transducers to control flow/volume-based pressure
 Allow continuous or pulsatile perfusion through the vasculature to
provide nutrients while removing metabolic waste products
 Monitoring and maintenance of physiological vascular pressure
 Monitoring and maintenance of proper gases supply
 Monitoring organ mechanics during repopulation
 Can include organ-specific biophysical stimuli (e.g. provide mechanical
ventilation in lung, provide mechanical stretch and electrical stimulation in
heart)
 Allow non-invasive or minimally invasive monitoring of relevant
biochemical and biophysical markers indicative of organ maturation and
function
 Allow automation of critical parameters
 Maintain sterility (disposable or easily sterilized components)
 Good manufacturing practices (GMP) amenable/Clinical grade bioreactors
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possibility to monitor biochemical and biophysical markers indic-
ative of organ maturation and function in a non-invasive manner.
Other issues are related to the application of physiological relevant
stimuli that can enhance tissue formation and functionality. The
principle bioreactor requirements for whole organ culture are
listed in Box 4. Extensive discussion on recent bioreactor devel-
opments is reported elsewhere (reviewed in [69]) [70–77].
Vascular and non-vascular routes have been employed to deliv-
er cells into whole organ-derived dECM scaffolds, mostly follow-
ing dynamic seeding procedures, which consist of introducing
cells at a specific concentration into the vascular perfusion line.
Following this methodology, researchers have recellularized the
vasculature and parenchyma of liver, heart, lung and kidney
(reviewed in [22–27]). Cells introduced into the vascular flow
may traverse the vascular lining through pores produced during
decellularization, then reaching the organ parenchyma. In this
regard, it has been proposed that the proper adjustment of flow
rates may reduce shear stress on cells, while minimizing the
potential damage on the dECM scaffold. Moreover, multiple
inoculations of cells are preferable than a unique one with the
same total cell number. Performing multiple cell infusions directly
into the liver vascular circuit in a step-wise manner led to more
than 85% cell engraftment [77–79], also showing a more efficient
distribution of cells across all regions of the organ-derived dECM
scaffold. Alternatively, direct injection of cells with a small gauge
needle by performing multiple injections throughout different
areas of organ parenchyma has shown less success [80]. Other
non-vascular routes commonly used to reintroduce cells are the
trachea in lungs [54,56–59] or the ureter in kidney [55,81–83].
So far, the large body of work regarding recellularization of whole
organ dECM scaffolds has been performed in small animal models
using different bioreactor settings, cell types and seeding condi-
tions (reviewed in [22–27]). The main problems encountered dur-
ing recellularization were the uncomplete re-endothelization of the
organ vasculature, and the insufficient repopulation of the organ
parenchyma [55,56,60]. Notably, recently this year, Guyette and
coworkers have partially repopulated whole decellularized humanPlease cite this article in press as: E. Garreta, et al., Mater. Today (2017), http://dx.doi.org/10hearts using a custom human heart bioreactor capable of providing
coronary perfusion and left ventricle wall mechanical stimulation,
showing metabolically active repopulated myocardial segments
after 14 days of organ culture [84]. Also Nichols and coworkers
have reported, for the first time, the development of a bioreactor
system to support recellularization of whole human paediatric lung
dECM scaffolds, identifying the main conditions and cell require-
ments necessary for bioengineering whole human lungs [85].
Moreover, many different cell types and sources have been
reported for recellularization strategies of different organs
(reviewed in [22–27]). Initial works made use of neonatal or fetal
cells derived from the organ of interest, showing retention of their
tissue-specific phenotype after seeding into the organ-derived
dECM scaffold together with relevant organ-specific functionality.
Overall, these works served as a proof-of-concept of the fabrication
of whole organs de novo by decellularization/recellularization
techniques. However, those findings also highlighted the necessi-
ty to find more amenable cell sources that could be easily expand-
ed and differentiated into functional and multiple cell lineages. In
this regard, hPSCs have been proposed as promising candidates
due to their self-renewal capacity and the potential to give rise to
any cell type in the body [86–88]. The use of hPSCs as a cell source
for the development of bioengineered organs based on dECM
scaffolds is further discussed in the following section.
Pluripotent stem cells: a long-standing cell source for
regenerative medicine
Pluripotent stem cells
Pluripotency is defined as the ability of a single cell to divide and
produce differentiated cells from the three germ layers of the
embryo [86–88]. The idea to generate functional tissues and organs
from pluripotent stem cells (PSCs) has been a long-standing goal in
stem cell biology, representing an unprecedented opportunity to
study development and even to heal degenerative diseases and
aging-related disorders. In this regard, the possibility to capture
and culture indefinitely hESCs from the pluripotent inner cell
mass (ICM) of the blastocyst has been a major breakthrough in the
area of regenerative medicine [86].
Before hESCs were first derived, seminal studies already tried to
answer how shape and pattern emerge from the simple beginnings
of an embryo, and even how specialized cells differentiate during
embryo development becoming organized into a 3D architectural
context (reviewed in [89]) [90]. Pursuing the idea to reprogram
differentiated cells to an ‘embryonic’ state, Takahashi and Yama-
naka in 2006 discovered that the pluripotent state found in hESCs
derived from the ICM could be artificially induced in a somatic cell
through the overexpression of just four transcription factors
(OCT4, SOX2, cMYC, and KLF4-OSKM) [87] (reviewed in [91]).
The produced cells, so called iPSCs, exhibited all the molecular and
functional features of ESCs. Importantly, in the last years human
iPSCs (hiPSCs) have shown to become instrumental platforms for
the study of human development and disease with the identifica-
tion, in some cases, of molecular and cellular mechanisms respon-
sible for disease gestation and progression (reviewed in [92]).
Overall, one major limitation in the field of hiPSC disease
modeling is the lack of a systemic context and disease-related
environmental cues [e.g., disorganized ECM, insufficient bio-
chemical signals from the niche, among others], opening new.1016/j.mattod.2016.12.005
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BOX 5
Extracellular matrix components used in hPSCs culture and differentiation
ECM components References
 Collagens are the most abundant ECM macromolecules found in our body. Among the 28 types of collagen that exist, collagen
IV and I have been widely used in hPSCs differentiation studies demonstrating to be implicated in mesodermal differentiation. In
addition, collagen’s ability to self-aggregate and crosslink makes it an attractive macromolecule for biomaterial science
[97]
 Laminin is a trimeric protein found in the basement membrane, which has been largely investigated for its influence in hPSCs
differentiation towards ectodermal tissues
[98]
 Fibronectin is an ECM protein highly expressed during the early stages of embryonic development, being essential for proper
development of the mesoderm and the neural tube. Generally, it is widely used as cell adhesion protein due to the presence of
the peptide sequence arginine-serine-aspartic acid (RGD) in its structure, which is implicated in integrin-mediated cell adhesion
[99,100]
 Matrigel is generated from the basement membrane of mouse sarcoma cells thereby containing a variety of ECM molecules
and growth factors. Laminin is the major constituent although collagen IV and proteoglycans also take part of its composition.
Since it is derived form basement membrane it provides a rich environment that has been largely used for the maintenance of
hPSCs as well as differentiation to many lineages including cells from the three germ layers, mesoderm, endoderm and ectoderm
Reviewed in [94–96]
 Cell-deposited ECM can be extracted from different cell types by first allowing the cells to produce their own ECM and then
removing them without disturbing the newly synthesized ECM structure and biochemical composition. Such cell-deposited ECM
has been then used as a coating for stem cell stemness and differentiation studies
[101]
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thology. In this regard, it has been recently shown that the proper
fine-tuning of 3D scaffolds recapitulated the abnormal contractili-
ty in hiPSC-derived cardiomyocytes from patients with long QT
syndrome type 3, and not when healthy counterparts were used.
Such platform also allowed for the screening of cardiotoxic com-
pounds in different 3D settings, highlighting the potential appli-
cation of these approaches for human disease modeling [93].
Differentiation strategies: from pluripotent colonies to
organoids/organogenesis in a dish
One of the major areas of research in the field of hPSCs has been
the development of protocols for the generation of functional cell
types suitable for disease modeling and cell replacement therapies.
Until recently, most protocols of differentiation relayed on the
generation of single cell populations rather than complete tissues.
However, in the last three years pivotal studies have demonstratedPlease cite this article in press as: E. Garreta, et al., Mater. Today (2017), http://dx.doi.org/10
FIGURE 2
The main strategies used for hPSCs differentiation include guided
differentiation in 2D monolayer cultures, the formation of embryoid bodies
and the induction of 3D self-organization giving rise to organoids. The
generation of organoids needs a higher cell culture complexity than the
other two approaches.
6that it is possible to generate 3D cultures of developing tissues
named organoids (reviewed in [94,95]).
After the first derivation of hESCs [86], different laboratories
worldwide explored hESCs capacity to undergo controlled differ-
entiation either in monolayer, by seeding cells in the presence of
different ECM protein coatings (major matrices used for the cul-
ture of hPSCs are described in Box 5) (reviewed in [94–96]) [97–
101], or as spheroid-like structures named embryoid bodies (EBs)
(Fig. 2). Although EBs can recapitulate several aspects of early
development (reviewed in [94]), as any other methodology, EB
formation still hampers the translation of this approach into a
clinical setting (e.g., low reproducibility and scalability). Never-
theless, all these advances have been fundamental for the proper
instruction of hPSCs to form self-organized tissue-specific orga-
noids including the optic cup, brain, intestine, liver and kidney
(reviewed in [94]).
Organoids are similar to in vitro derived EBs, but they can
recapitulate a large number of biological processes related with
spatial and temporal organization of heterogeneous tissue-specific
cells within the 3D structures (Fig. 2). Even in some cases, orga-
noids have proved to exhibit physiological functions being close
to the in vivo setting. In this regard, kidney organoids derived from
hiPSCs have been recently shown to contain multiple nephron
segments surrounded by nascent blood vessels, being able to
respond in front of nephrotoxic compounds [102]. Despite these
findings, most hPSC-derived organoid models only represented
single or partial components of a tissue, hindering the proper
control of cell-cell interactions, cell-matrix interplay, and cell
organization. Moreover, common hurdles in organoid technolo-
gies are being related to incomplete maturation of hPSC-derived
cell types and the lack of vascularization.
Bioengineering approaches for hPSCs differentiation: dECMs as
biomimetic platforms for generating tissues on-demand
Bioengineering approaches can be used to overcome major issues
associated with hPSCs differentiation as maturation and function-
ality. In this regard, matrigel has been a fundamental matrix for
organoid methodologies, including cerebral, optic cup and intesti-
nal organoids from hPSCs (reviewed in [94,95]). However, matrigel.1016/j.mattod.2016.12.005
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BOX 6
3D bioprinting techniques
Bioprinting
techniques
Additive unit Actuation method Cell
viability
Commercial
bioprinter
Bioink
viscosity
Disadvantages Advantages References
Inkjet printing Drop  Piezoelectric pulse
 Thermal induced
pulse
>85% Yes Low  Microvalves for inkjet are
fragile
 Requires fast material
gelation/stabilization
 Height of 3D constructs
limited due to low bioink
viscosity
 High control on the amount
of material deposited (1 pL to
0.1 nL per drop)
Reviewed
in [12]
Laser assisted
bioprinting
Drop  Laser induced pulse >95% No Medium-high  High cost of future
commercial bioprinters
 Long fabrication time
 Long preparation time of
material ribbons
 Low diversity of bioink for
ribbon preparation
 High printing resolution
 Single cell deposition
Reviewed
in [12]
Micro extrusion Material strain  Pneumatic pressure 40–95% Yes Medium-high Pneumatic pressure
 Cells may suffer important
shear stress
 Medium printing accuracy
 Low printing resolution
Pneumatic pressure
 Abrasive materials can be
used
 Disposable cartridge that
avoids cross-contamination
 Non mechanical parts
 Used by most of commercial
bioprinters due to its
robustness and simplicity
 Allows printing cell high
density
Reviewed
in [10,12]
 Mechanical pressure Mechanical pressure
 Cells may suffer important
shear stress
 Medium printing accuracy
 Low printing resolution
 Mechanical parts make this
system more fragile
 Screw based system require
cleaning of mechanical parts
Mechanical pressure
 Abrasive materials can be
used
 Piston based systems uses
disposable syringes
 Allows printing cell high
density
Stereolithography
(SLA)
Cured bioink
voxel
 Laser based curing
 UV and visible light
projection curing
>85% Yes Medium  Only can be used with light
crosslinkable bioinks
 Multicellular structures are
challenging
 Printer are not specifically
designed for biofabrication
 Affordable
 High printing velocity
Reviewed in
[10,123,127,128]
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lead to important differences in experimental outcomes [103].
Along this line, biomaterials can be used to create stem-cell-like
niches providing key elements to control the regulation of stem
cell fate and function. Indeed, material properties have been often
designed to mimic physiologically relevant ECM stiffness, topog-
raphy, and adhesion-ligand type, density and affinity. These fea-
tures, when combined with hPSCs have led to the derivation of
protocols for hPSCs differentiation building personalized tissue
constructs using human organ-derived dECM scaffolds
[43,84,104,105], and even for partially or totally reconstructing
mouse [106] and human whole organs [84,105].
Ott and coworkers recently reported for the first time the whole
repopulation of decellularized human hearts with hiPSCs-derived
cardiomyocytes [84]. In the same line, our group developed a rapid
protocol for the generation of human heart grafts by co-culturing
hPSC-derived cardiomyocytes on top of 400 micrometers-thick
slices of human ventricular dECM scaffolds [43].
Importantly, rat and human lung dECM scaffolds have been
also recently shown to be repopulated with endothelial and peri-
vascular cells differentiated from hiPSCs [105]. Concerning kid-
ney, only two works have investigated the role of rhesus monkey
kidney dECM scaffolds on hPSCs renal differentiation [40,107].
Alternatively, 3D bioprinting technology have opened new
venues for the bottom-up generation of tissue and organ analogues
by the deposition in an additive layer-to-layer approach of differ-
entiated hPSCs and biomaterials, specifically arranged to repro-
duce native 3D architectures (reviewed in [11,12,95]).
Nevertheless, attempts to generate hPSCs derived bioprinted con-
structs are still in its infancy, with only one report on the genera-
tion of mini livers from hPSCs [16].
Tissue engineering of human organ analogues by 3D
bioprinting
3D bioprinting techniques
Bioprinting techniques aim to perform simultaneous deposition of
single or multiple combinations of living cells together with
supportive matrices containing biochemical and biophysical cues
(altogether termed as bioink). In this manner, organs or tissue
analogues are constructed following a predefined architecture in
3D (reviewed in [12–14]). These methodologies are generally clas-
sified based on the technology used to generate the structures of
the cell-laden material as follows:
Inkjet bioprinting, also referred as ‘drop-on-demand printers’
appeared early in 2003 [108]. Firstly developed inkjet printers
modified commercially available two-dimensional (2D) ink-based
printers by replacing the ink in the cartridge by a biological
material, and the paper, by an electric-controlled elevator that
moves on the z direction providing three-dimensionality
(reviewed in [12]) [109]. Nowadays, inkjet printers make use of
nozzles that generate isolated droplets of cell-laden material by
means of piezoelectric [110] or thermal (reviewed in [111]) actu-
ation systems. In this manner, by means of either acoustic waves or
thermal forces, respectively, liquid drops are ejected onto a sub-
strate. In the last years, inkjet bioprinting has allowed for the
efficient introduction of gradients of cells or growth factors along
the 3D constructs by the modification of drop densities and size
[17,112,113]. Despite this major advances, one common drawbackPlease cite this article in press as: E. Garreta, et al., Mater. Today (2017), http://dx.doi.org/10
8in inkjet printing is the need to work with biological materials in
liquid forms, which in most of the cases demand a fast polymeri-
zation procedure post-printing (e.g., by either chemical, pH or
ultraviolet mechanisms, among others). All these procedures di-
rectly affect the bioprinting process, compromising the chemical
and mechanical properties of ECM-derived materials. As reviewed
elsewhere, other disadvantages are related to the impediment of
building 3D cell-laden constructs with general tissue size, nozzle
clogging when using solutions with high cell densities, and cell
viability constraints (related to the use of cross-linkers) (reviewed
in [12]). Nevertheless, inkjet-based bioprinters have become a
massive used technology reducing costs and facilitating the use
of free designs and softwares worldwide. Current research is now
focused in the development of novel technologies allowing the use
of multiple cell types and materials.
Microextrusion systems appeared as a modification of inkjet prin-
ters. Here the extrusion of the material takes place through micro-
metric apertures (usually a needle with inner diameters that range
from few to hundred micrometers). By applying a continuous
force, this technique allows to print uninterrupted cylindrical
lines. Commonly, these systems robotically extrude biological
materials by pneumatic or mechanical dispensing systems onto
a substrate. It has been reported that almost all kind of hydrogels
with varying viscosities, as well as aggregates with high cell density
can be printed with this approach (reviewed in [10,12]). Compared
to inkjet printing, microextrusion printing enables the deposition
of large amount of cells, allowing the generation of constructs with
general tissue size. So far, high concentrations of hydrogels such as
alginate, fibrin and Pluronic F-127, among others, have proved to
be effective when producing stable 3D cell-laden structures [114–
120]. Importantly, microextrusion systems have been particularly
effective when printing multicellular tissue spheroids that further
self-assemble into the desired 3D structure (reviewed in [15]).
Although all the advantages described here, one of the major
limitations of this technique is the decreased cell viability resulting
from the shear stress when cells are in viscous fluids during the
extrusion process [121]. Thus, one of the main challenges consists
in the retention of cell viability and printing speed without
decreasing pressure or reducing nozzle size. Several tissues have
been fabricated using this system, including branched vascular
trees, aortic valves, and in vitro tumor models (reviewed in [12]).
Recently, Atala and coworkers have lead the first work on the
fabrication of bioprinted tissue functional constructs in vitro and in
vivo for mandible bone, ear-shaped cartilage and organized skeletal
muscle at human-scale [18].
In laser-assisted bioprinting (LABP) drops of cell-laden biomaterials
are generated after laser pulses. The falling bioink droplet is further
collected on the substrate and crosslinked, avoiding shear stress and
resulting in high cell viabilities, even when using highly viscous
materials. This recent methodology relies on the use of a laser pulse
that creates a high-pressure bubble on a ribbon containing the
material to be printed, thereby generating a bioink droplet. LABP is
nozzle-free, thus minimizing clogging-related issues. Moreover, the
achieved resolution allows the delivery of single-cells on each drop.
Since this system generates scaffold-free 3D cell constructs through
a layer-by-layer manner, lately LABP is becoming used for the
deposition of different living cells and biomaterials in a well-
defined 3D structure. Besides these advantages, still possible side.1016/j.mattod.2016.12.005
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are related to the preparation of cell-laden ribbons (specific for each
cell type and hydrogel, hindering scaling-up procedures) and the
deposition of metallic residues in the final bioprinted construct.
Similarly, targeting and positioning cells becomes difficult because
of the nature of the ribbon cell coating (reviewed in [12]). To date,
few works took advantage of this system in regenerative medicine
[19,122], and the high cost of LABP precludes their use for many
researchers worldwide.
Stereolithography (SLA) was initially used to create cell-free scaf-
folds but the increasing development in the formulations of new
cross-linkable materials allowed the use of SLA for 3D bioprinting
(reviewed in [123]) [124]. In SLA, the laser focusing point moves on
the X/Y axes along the uncured bioink, while the stage where the
material is polymerized lowers allowing polymerization. Lately,
direct light projection (DLP) has emerged as an affordable and versa-
tile variant of SLA. In DLP, the light from a digital micro mirror
device or projector is used for curing photocrosslinkable hydrogels
in a layer-by-layer approach. By curing the structures plane-by-
plane, DLP offers enormous advantages in front of SLA (e.g.,
printing time is not depending on the design complexity of each
plane). DLP has been recently used for generating biocompatiblePlease cite this article in press as: E. Garreta, et al., Mater. Today (2017), http://dx.doi.org/10
BOX 7
3D bioprinting of cell-laden tissue constructs
3D bioprinter needs  Allow combination of micr
printing procedure
 Have at least two hydrogel-
in the same printed constru
 Possess temperature contr
 Allow optical monitoring o
 Allow the interchange of m
 Precise control of the pres
 Allow the use of different 
plates)
 Posses an accurate calibra
 Posses a source of light (U
 Work under sterile conditio
Key material properties for 3D bioprinting  Printability defines the suita
material physicochemical pr
mechanism) under the cond
 Biocompatibility refers to th
activity, including the facilitat
regeneration, without elicitin
 Biodegradability describes t
material. Degradation kinetic
generated should be nontox
 Biomechanical properties o
construct and match tissue s
 Biomimicry refers to the ab
3D bioprinting processing parameters  The four main variables th
design fidelity are: the needl
the linear write speed
 These variables are balance
being possible to dispense a
 These aforementioned var
 Changes on environmental
 As printed structures increa
pattern is necessary
 The printing time should b
humidity or material biocomscaffolds [125–127], and more recently Wang and coworkers dem-
onstrated that DLP enabled for the fabrication of 3D cell-laden
structures with resolutions of 50 micrometers, and reaching 85%
cell viability when encapsulating human fibroblasts [128]. DLP and
SLA offer new alternatives for the fabrication of 3D bioconstructs
with precise micro- and nano-architecture, being affordable sys-
tems in terms of costs.
A summary of the aforementioned bioprinting techniques is
presented in Box 6.
3D bioprinting of cell-laden hydrogels
Since 2000, when rapid prototyping technologies were first
adapted for the deposition of cell-laden hydrogel 3D structures
in cell-compatible printing conditions, researchers all over the
world have tried to produce biological tissue-like constructs using
different cell types and hydrogel formulations. The basic 3D
bioprinting equipment needs when aiming to fabricate cell-laden
3D structures are described in Box 7.
Current efforts are devoted to develop novel biomaterial for-
mulations that can mimic the complexity of the native ECM–a
concept called biomimicry – with an impact for bioprinting appli-
cations. ECM composition and rigidity have proved to dictate cell.1016/j.mattod.2016.12.005
o-extrusion, fused deposition and inkjet printing at the same time during a
compatible printing heads, which facilitates deposition of different cell types
ct
ol systems for printing heads and substrate
f the printing process
aterial cartridges during the printing procedure
sure applied during the printing process
substrates to print the desired 3D tissue construct (e.g. petri dish, multiwall
tion system for needle tip positioning
V, blue light) for light-crosslinking hydrogels
ns
bility of a material for a specific printing process and largely depends on the
operties (viscosity, shear thinning, yield stress, hydrogel crosslinking
itions provided by the bioprinting instrument
e ability to perform as a material that will support the appropriate cellular
ion of molecular and mechanical signaling systems, in order to optimize tissue
g any undesirable host responses
he biological processes inside the body that cause a gradual breakdown of a
s should be matched to the novo tissue formation and the byproducts
ic
f the material should provide sufficient structural integrity to the printed
pecific biomechanic requirements
ility of reproduce tissue-specific endogenous material compositions
at need to be balanced to optimize the printing procedure and ensure the
e/tip size, the distance from the tip to the surface, the material flow rate and
d when the leading edge of the printed bioink is continual with the needle,
 uniform strand
iables need to be optimized for every different material used
 conditions such as humidity and temperature may influence printing fidelity
se in complexity, the incorporation of support structures within the fabricated
e considered, since extended periods of time at non-optimal temperature,
patibility will affect both material properties and cell viability
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rigidity ranges from 0.2–5 kPa in soft tissues as brain, to 15,000 kPa
in bone, being an important parameter to be considered when
aiming to design 3D tissue and organ analogues.
Besides the need to be biocompatible and biodegradable, a
biomaterial formulation for bioprinting must possess suitable
physicochemical properties in order to fabricate 3D constructs
with high resolution and printing fidelity – a characteristic named
printability (Box 7) (reviewed in [130–132]). In addition, it must
also be optimized in order to minimize stress-induced damage to
the cells and biological components, which occur during the
deposition process (reviewed in [130–132]). The ideal hydrogel
formulation should reach a compromise between preserving cell
viability and matching optimal printability.
Viscosity, shear thinning and yield stress of a defined bioink will
directly affect printing fidelity during the biofabrication process.
Similarly, the specific processing parameters will define the shear
stress that cells will suffer during the deposition and the time
required for the fabrication of a given 3D construct (e.g., tip size,
flow rate, temperature; Box 7). Another important outcome is the
maintenance of sufficient structural integrity by the bioprinted 3D
construct, which will be mainly dependent on the gelation of thePlease cite this article in press as: E. Garreta, et al., Mater. Today (2017), http://dx.doi.org/10
FIGURE 3
Schematic representation of a 3D bioprinting system consisting of a
computer aided 3-axis stage controller and a deposition module including
three different print heads connected to a pressure controller (a). Computer
aided design and computer aided manufacturing (CAD/CAM) process for
3D bioprinting of a human size kidney. A 3D CAD model generated from
medical imaging data (CT: computed tomography; MRI: magnetic resonance
imaging) produces a visualized motion program which dictates the XYZ
stage movements to generate the 3D bioprinted kidney prototype (b).
10hydrogel formulation. Natural and synthetic hydrogels applied to
3D bioprinting and their correspondent gelation mechanism are
further reviewed elsewhere (reviewed in [130–133]).
Elegant works have demonstrated the feasibility of 3D bioprint-
ing for the generation of several tissues, including bone [18], skin
[19], vascular grafts [118,120,134], tracheal supports [135], heart
[20,117,136] and cartilage [18,20] tissue structures, using several
cell sources such as human umbilical vein endothelial cells, mes-
enchymal stem cells, human meniscus cells and fibroblasts
(reviewed in [10,12]). However, the fabrication of human size organ
analogues with complex architectures requires a more elaborate 3D
bioprinting strategy, usually involving the co-deposition of other
material components (such as supportive and sacrificial materials),
together with cell-laden hydrogels, ensuring sufficient structural
integrity to the printed construct while maintaining an internal
porosity (Fig. 3). In this regard, the recent work by Atala and
coworkers provides a 3D bioprinting platform for the production
of tissues for human applications, paving the way for future build-
ing of solid organs [137].
Acellular organ-specific dECM hydrogels for 3D bioprinting
As decellularization protocols emerged, hydrogels made from
decellularized tissues including urinary bladder [138], heart
[139], liver [140], dermis [141], adipose tissue [142], bone [143],
and lung [144], among others, were developed and reported to
support growth and function of different cell types. However, it is
not until very recently that tissue-specific dECM hydrogels have
been envisioned as a new class of hydrogels for 3D bioprinting
[20,145–147]. Nowadays, one of the main hurdles when using
dECM hydrogels as bioinks relies on their low viscosity, which
inevitably compromise shape fidelity of the bioprinted 3D con-
struct, worsening printing resolution.
To date, only few studies have used dECM hydrogels for 3D
bioprinting, applying different strategies to improve their print-
ability [20,145–147]. Pati and coworkers were the first to success-
fully apply dECM hydrogels for 3D bioprinting. Their strategy
consisted on the co-deposition of an open porous structure of
polycaprolactone (PCL) as a supportive material, together with
the cell-laden dECM hydrogel made from cartilage, heart or adipose
porcine tissues [20]. Recently, the same group used skeletal muscle-
derived dECM hydrogels for 3D printing of muscle constructs [147].
Following a different strategy, Skardal and coworkers elegantly
developed modular hyaluronic acid and gelatin-based hydrogels
supplemented with porcine liver, cardiac and skeletal muscle
dECM solutions. Following a two-step crosslinking procedure,
the authors achieved printable bioinks with different stiffness
ranging from 100 Pa to 20 kPa, thus allowing the possibility to
mimic the mechanical characteristics of different tissues in the
body [145]. Other recent work by Jang and coworkers took advan-
tage of pig heart dECM to prepare cardiac-specific hydrogels that in
combination with human cardiac progenitor cells were used to
fabricate 3D bioprinted cardiac constructs. The gelation of cardiac
dECM hydrogels was based on thermal and chemical crosslinking
using vitamin B2 via UVA activation [146].
Future outlook
A major limitation when generating artificial organs on demand
stands in the development of techniques to properly reintroduce.1016/j.mattod.2016.12.005
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plete organ re-endothelization and functional activity. Due to
their intrinsic characteristics, hPSCs have been envisioned as an
optimal cell source for the generation of complex tissue structures
like the organ parenchyma and the vascular system, offering major
advantages when compared with adult somatic or stem cells for
the same purposes. Moreover, targeted genome editing, as CRISPR
platform, is a powerful tool to manipulate and correct disease
related genes in patient-derived hiPSCs, allowing for the genera-
tion of autologous-corrected cells suitable for disease modeling
and drug screening [148]. We believe that targeted genome editing
approaches combined with recent progress in the formation of
patient-specific hiPSCs-derived organoids could provide an un-
precedented source of organ-specific cell types suitable for cell
replacement therapies. In this regard, common efforts on the
definition of chemically defined conditions to culture hPSC-de-
rived organ-specific cells has led to the examination of novel
approaches guiding hPSCs maturation. Following these questions,
different works have relayed on the use of human dECM scaffolds
together with hPSCs in order to generate human tissue graftsPlease cite this article in press as: E. Garreta, et al., Mater. Today (2017), http://dx.doi.org/10
FIGURE 4
3D bioprinting approach for the development of patient-specific organ analogue
progenitor cells in 2D monolayer cultures (representative image for SALL1 and W
further induced to develop into kidney organoids (representative image for PAX8
(c). The combination of kidney dECM-based hydrogels (d) with patient iPSC-deriv
3D renal constructs (representative image for PAX8 renal structures developed in
generation of tissue and organ analogues suitable for regenerative medicine app
among others).[43,84,104], and even to reconstruct whole organs [84,105], re-
vealing the impact of organ-derived dECMs on the proper instruc-
tion of hPSCs fate and function [40,43,84].
Alternatively, 3D bioprinting represents a formidable technol-
ogy for artificial organ generation. Besides the different limitations
of this nascent technology (e.g., printing resolution and time,
combination of different bioinks simultaneously, among others),
the possibility to print human-scale tissues has been recently
demonstrated [18]. In this regard, seminal studies have already
proved the feasibility to print 3D tissue constructs using organ-
specific dECM hydrogels as biomimetic bioinks [20,145–147],
opening the door to the fabrication of novel bioink formulations
matching cytocompatibility and mechanical strength require-
ments for 3D bioprinting.
Overall, we believe that recent advancements in the fields of
hPSCs differentiation together with organ-derived dECM scaffolds
or novel dECM-based hydrogels aimed for 3D bioprinting repre-
sent a step forward in the fabrication of autologous functional
tissues on-demand (Fig. 4 and Box 8). To this end, multidisciplin-
ary research in the field of engineering, biomaterials science, stem.1016/j.mattod.2016.12.005
s such as kidney. Patient-specific iPSCs (a) are differentiated into renal
T1 double positive renal progenitors by immunofluorescence) (b) that are
 and E-cadherin positive 3D renal-like structures by immunofluorescence)
ed renal progenitor cells could be used for the biofabrication of specialized
to printed kidney dECM-based hydrogels) (e). This approach renders to the
lications (e.g., disease modeling, drug screening, cell replacement therapies,
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BOX 8
Challenges and future perspectives
Research area Specific challenges Future outcomes
Decellularization  Standardization of decellularization protocols for each
specific organ
 Systematic evaluation of immunologic response and the
possibility of using dECM scaffolds from different species
 Robust production of organ-derived dECM scaffolds
 Determination of the need of immunosuppressive drugs
after transplantation. Increase the tissue source, overcoming
donor shortage
Recellularization  Improved seeding methodologies for complete re-
endothelization of the organ vascular bed and parenchyma
recellularization
 Novel bioreactor systems with optimal control over the
culture conditions (oxygen delivery, biophysical stimulation,
continuous monitoring of functional parameters)
 Optimal vascularization
 Determination of organ biochemical/biophysical
parameters during recellularization, and end-points for each
organ
 Definition of common guidelines for the assessment of
organ mechanics Preservation of bioengineered organs
before transplantation
 Functional evaluation in large animal models
Human pluripotent
stem cells
 Standardized protocols for expansion and differentiation to
large cell numbers
 Purification of hPSC-differentiated cells and identification
of optimal cell culture conditions (growth factors, cytokines)
for cell phenotype maintenance
 Identification of hPSC-derived progenitor cell types suitable
for engraftment and maturation into dECM scaffolds
 Repopulation of organ-derived dECM scaffolds with
multiple hPSC-derived progenitor cell types specific for each
organ compartment, and in sufficient cell number to achieve
comparable native organ cell densities
 Generation of personalized human bioengineered organ
equivalents with optimal functional activity
3D bioprinting  Development of novel cell-compatible hydrogels with
tailored viscosity and biochemical composition
 Monitoring of bioink flow rate with automatic adjustment
of printing conditions
 Present alignment capability on previously printed
constructs
 Improve bioprinting full automation
 Development of bioreactors for tissue/organ growth and
maturation post-processing
 Bioprinting of cell-laden structures with increased
mechanical strength, bioactivity and cell viability
 Increased printing fidelity
 Step-wise fabrication of complex multicellular structures
 Rapid production of 3D printed constructs, thereby
improving cell viability
 Generation of functional tissue/organs
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eviewcell biology and medicine will be essential to further succeed in the
biofabrication of autologous organs for future clinical replacement
strategies.
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